Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Carotid Plaque Composition by Magnetic Resonance Imaging During Lipid Lowering Therapy

Trial Profile

Carotid Plaque Composition by Magnetic Resonance Imaging During Lipid Lowering Therapy

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atorvastatin (Primary) ; Colesevelam (Primary) ; Niacin (Primary)
  • Indications Atherosclerosis
  • Focus Therapeutic Use
  • Acronyms CPC
  • Most Recent Events

    • 16 May 2022 Status changed from active, no longer recruiting to completed.
    • 16 May 2022 The primary outcome Changes in carotid plaque composition, as assessed by MRI was changed to Annualized LRNC Volume Change in Carotid Plaque Composition, as Assessed by MRI and Annualized LRNC and Wall Volume Changes in Carotid Plaque Composition, as Assessed by MRI, according to ClinicalTrials.gov record.
    • 01 Aug 2021 Results of a pooled analysis assessing the potential mechanisms for this lack of cardioprotection by quantifying the HDL proteome of subjects in 2 niacin clinical trials ( CPC study (Carotid Plaque Composition) and the HDL Proteomics substudy of the AIM-HIGH trial) published in the Arteriosclerosis Thrombosis and Vascular Biology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top